Patents by Inventor Yuri Ivashchenko

Yuri Ivashchenko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isoquinoline derivatives
    Patent number: 8722671
    Abstract: The invention relates to 6-piperidinyl-substituted isoquinoline derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: May 13, 2014
    Assignee: Sanofi
    Inventors: Oliver Plettenburg, Armin Hofmeister, Dieter Kadereit, Stefan Peukert, Sven Ruf, Kurt Ritter, Matthias Loehn, Yuri Ivashchenko, Peter Monecke, Matthias Dreyer, Aimo Kannt
  • Isoquinoline derivatives
    Patent number: 8501736
    Abstract: The invention relates to 6-piperidinyl-substituted isoquinoline derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.
    Type: Grant
    Filed: December 20, 2007
    Date of Patent: August 6, 2013
    Assignee: Sanofi
    Inventors: Oliver Plettenburg, Armin Hofmeister, Dieter Kadereit, Stefan Peukert, Sven Ruf, Kurt Ritter, Matthias Loehn, Yuri Ivashchenko, Peter Monecke, Matthias Dreyer, Aimo Kannt
  • REVERSIBLY IMMORTALIZED CELLS AS WELL AS METHODS RELATING HERETO
    Publication number: 20130171731
    Abstract: The present invention relates to methods of producing a reversibly immortalized cell, cells obtainable by the above method, eukaryotic cells comprising one or more nucleic acid(s) coding for one or more immortalizing protein(s) and methods of re-differentiating these cells.
    Type: Application
    Filed: May 4, 2010
    Publication date: July 4, 2013
    Applicant: SANOFI
    Inventors: Yuri Ivashchenko, Thea Hennig
  • CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES
    Publication number: 20110251226
    Abstract: The invention relates to 6-cyclohexylamine-substituted isoquinolone derivatives of the formula (I) or isoquinoline derivatives of the formula (I?) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.
    Type: Application
    Filed: June 15, 2011
    Publication date: October 13, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Oliver Plettenburg, Armin Hofmeister, Dieter Kadereit, Stefan Peukert, Sven Ruf, Kurt Ritter, Matthias Loehn, Yuri Ivashchenko, Peter Monecke, Matthias Dreyer, Aimo Kannt
  • ISOQUINOLINE DERIVATIVES
    Publication number: 20110245248
    Abstract: The invention relates to 6-piperidinyl-substituted isoquinoline derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.
    Type: Application
    Filed: June 15, 2011
    Publication date: October 6, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Oliver Plettenburg, Armin Hofmeister, Dieter Kadereit, Stefan Peukert, Sven Ruf, Kurt Ritter, Matthias Loehn, Yuri Ivashchenko, Peter Monecke, Matthias Dreyer, Aimo Kannt
  • High-throughput Enzyme-linked immuno absorbent assay (ELISA) for determination of Rho-kinase (ROK) activity
    Patent number: 7858328
    Abstract: The invention is referring to an assay for measuring the activity of a ROK (Rho kinase) protein by means of a biotinylated peptide.
    Type: Grant
    Filed: December 7, 2005
    Date of Patent: December 28, 2010
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Matthias Loehn, Yuri Ivashchenko, Elke Kessler
  • Isoquinoline Derivatives
    Publication number: 20090088429
    Abstract: The invention relates to 6-piperidinyl-substituted isoquinoline derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.
    Type: Application
    Filed: December 20, 2007
    Publication date: April 2, 2009
    Applicant: SANOFI-AVENTIS
    Inventors: Oliver PLETTENBURG, Armin HOFMEISTER, Dieter KADEREIT, Stefan PEUKERT, Sven RUF, Kurt RITTER, Matthias LOEHN, Yuri IVASHCHENKO, Peter MONECKE, Matthias DREYER, Aimo KANNT
  • HIGH-THROUGHPUT ENZYME-LINKED IMMUNO ABSORBENT ASSAY (ELISA) FOR DETERMINATION OF RHO-KINASE (ROK) ACTIVITY
    Publication number: 20090017478
    Abstract: The invention is referring to an assay for measuring the activity of a ROK (Rho Kinase) protein by means of a biotinylated peptide.
    Type: Application
    Filed: December 7, 2005
    Publication date: January 15, 2009
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Matthias Loehn, Yuri Ivashchenko, Elke Kessler
  • Variants of TRAF2 which act as an inhibitor of TNF-alpha (TNFalpha) signaling pathway
    Publication number: 20070015699
    Abstract: The present invention relates to variants of TRAF2 which demonstrate the ability to inhibit the TNF ? signaling pathway. In particular, applicants have isolated a splice variant of TRAF2 referred to hereinafter as “TRAF2 truncated” or “TRAF2TR” and a TRAF2 expression construct with enhanced dominant negative properties, hereafter referred to as “TRAF2 truncated-deleted” or “TRAF2TD”. Both TRAF2TR and TRAF2TD have the ability to inhibit the TNF ? signaling pathway and in TRAF2TD, this ability is greatly enhanced, greatly reducing the response to TNF ? binding.
    Type: Application
    Filed: December 5, 2005
    Publication date: January 18, 2007
    Inventors: George Searfoss, Marco Pagnoni, Yuri Ivashchenko, Kun Guo, Kenneth Clark
  • Akt nucleic acids, polypeptides, and uses thereof
    Publication number: 20050142603
    Abstract: The present invention relates to human Akt3 proteins and polypeptides. The invention also relates to isolated nucleic acids encoding human Akt3, to vectors containing them and to their therapeutic uses, in particular for gene therapy. Expression of Akt3 inhibits cell death associated with hypoxia, apoptosis or necrosis.
    Type: Application
    Filed: February 23, 2005
    Publication date: June 30, 2005
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: Kun Guo, Marco Pagnoni, Kenneth Clark, Yuri Ivashchenko